Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-10-27
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from a person's white blood cells may help the body build an
effective immune response to kill tumor cells. Monoclonal antibodies, such as trastuzumab,
can block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving vaccine
therapy together with trastuzumab and vinorelbine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with
trastuzumab and vinorelbine works in treating patients with locally recurrent or metastatic
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
National Cancer Institute (NCI) Susan G. Komen Breast Cancer Foundation